PE-22-28 Dosage Calculator
PE-22-28 is a synthetic heptapeptide (7 amino acids) derived from spadin, a naturally occurring fragment of the sortilin propeptide.
100mcg · Daily
Summary: Add 2mL BAC water to your 5mg vial. Draw to 4.0 units on a U-100 syringe for a 100mcg dose. This vial will last 50 doses.
Cycle Planner
PE-22-28 Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~23 hours (functional, animal data)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
PE-22-28 Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 100mcg | Daily |
| Moderate | 200mcg | Daily |
| Aggressive | 400mcg | Daily |
Note: Shortened spadin analog. TREK-1 potassium channel blocker (IC50 0.12 nM). Derived from sortilin propeptide. Animal research only — no human trials. Intranasal preferred for CNS access.
About PE-22-28
PE-22-28 is a synthetic heptapeptide (7 amino acids) derived from spadin, a naturally occurring fragment of the sortilin propeptide. It acts as a potent blocker of TREK-1 two-pore potassium channels in the brain, with an IC50 of 0.12 nM — roughly 300-fold more potent than the parent compound spadin. In animal models, PE-22-28 produces rapid antidepressant-like effects within 4 days of treatment, compared to the 3-4 weeks typical of SSRIs. It stimulates hippocampal neurogenesis, increases BDNF expression, and modulates serotonergic signaling. PE-22-28 also shows improved in vivo stability over spadin, with a functional duration of approximately 23 hours versus 7 hours. Preclinical stroke research has demonstrated neuroprotective effects, including reduced infarction size and improved motor and cognitive recovery. All current evidence comes from rodent studies — there are no published human clinical trials. This peptide remains strictly a research tool and should be approached with appropriate caution given the absence of human safety data.